Cargando…

Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA

Background: Rheumatoid arthritis (RA) is a systemic autoimmune disease in which synovial fibroblasts (SF) play a key role. Baricitinib and Tofacitinib both act intracellularly, blocking the ATP-binding side of JAK proteins and thereby the downstream signalling pathway via STAT-3. Therefore, we inves...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amrhein, Jan, Drynda, Susanne, Schlatt, Lukas, Karst, Uwe, Lohmann, Christoph H., Ciarimboli, Giuliano, Bertrand, Jessica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556031/ https://www.ncbi.nlm.nih.gov/pubmed/32927842 http://dx.doi.org/10.3390/ijms21186632

Ejemplares similares

Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life
por: Deprez, Valentine, et al.
Publicado: (2020)

Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data
por: Barbulescu, Andrei, et al.
Publicado: (2022)

Differential Effect of Cobalt and Chromium Ions as Well as CoCr Particles on the Expression of Osteogenic Markers and Osteoblast Function
por: Drynda, Andreas, et al.
Publicado: (2018)

Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis
por: Iwamoto, Naoki, et al.
Publicado: (2021)

Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations
por: McInnes, Iain B., et al.
Publicado: (2019)

Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
por: Harrington, Robert, et al.
Publicado: (2023)

Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review
por: Álvarez-Reguera, Carmen, et al.
Publicado: (2022)

Physiologically‐Based Pharmacokinetic Modelling to Investigate Baricitinib and Tofacitinib Dosing Recommendations for COVID‐19 in Geriatrics
por: Wang, Ziteng, et al.
Publicado: (2022)

JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib
por: Traves, Paqui G, et al.
Publicado: (2021)

IgA Vasculitis Developed as an Adverse Effect of Tofacitinib Taken for Rheumatoid Arthritis
por: Itoh, Izumi, et al.
Publicado: (2019)

Characteristics of patients initiating treatment with baricitinib and outcomes at follow-up: analysis of BSRBR-RA Registry data
por: Edwards, Christopher J, et al.
Publicado: (2023)

Identification of novel off targets of baricitinib and tofacitinib by machine learning with a focus on thrombosis and viral infection
por: Faquetti, Maria L., et al.
Publicado: (2022)

Effects of TIMP-1 and TIMP-3 gene transfer on invasiveness, proliferation and apoptosis of rheumatoid arthritis (RA) synovial fibroblasts (RA-SF)
por: Pap, T, et al.
Publicado: (2002)

Which is the Ideal JAK Inhibitor for Alopecia Areata – Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway
por: Sardana, Kabir, et al.
Publicado: (2023)

Massive nodulous lesions on hands and feet in a RA patient and improvement under baricitinib treatment
por: Valor-Méndez, Larissa, et al.
Publicado: (2020)

Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study
por: van der Heijde, Désirée, et al.
Publicado: (2018)

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
por: Dougados, Maxime, et al.
Publicado: (2017)

Comparative Efficacy and Safety of Peficitinib Versus Tofacitinib and Baricitinib for Treatment of Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis
por: Tanaka, Yoshiya, et al.
Publicado: (2021)

One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib
por: Bergman, Martin, et al.
Publicado: (2023)

Effects of Single Nucleotide Polymorphism Ala270Ser (rs316019) on the Function and Regulation of hOCT2
por: Frenzel, Dominik, et al.
Publicado: (2019)

Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial
por: Michaud, Kaleb, et al.
Publicado: (2019)

Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial
por: Taylor, Peter C., et al.
Publicado: (2019)

Erratum: Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
Publicado: (2017)

Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE
por: Yang, Yue, et al.
Publicado: (2020)

Efficacy and drug persistence of baricitinib monotherapy is similar to combination therapy in patients with active RA: a prospective observational study
por: Bayat, Sara, et al.
Publicado: (2022)

Organic cation transporter 3 mediates cisplatin and copper cross-resistance in hepatoma cells
por: Guttmann, Sarah, et al.
Publicado: (2017)

Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA?
por: Kwok, Seung-Ki
Publicado: (2014)

Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting
por: Miyazaki, Yusuke, et al.
Publicado: (2021)

Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies
por: Gialouri, Chrysoula G., et al.
Publicado: (2023)

Assessing the Solubility of Baricitinib and Drug Uptake in Different Tissues Using Absorption and Fluorescence Spectroscopies
por: Mohammadi-Meyabadi, Roya, et al.
Publicado: (2022)

Application of Baricitinib in Dermatology
por: Zhang, Jingya, et al.
Publicado: (2022)

Tofacitinib
Publicado: (2012)

Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis (RA): A Retrospective Study From Two Centers in Jeddah, Saudi Arabia
por: Alzahrani, Zeyad, et al.
Publicado: (2022)

Assessment of the association of baseline anti-CarbV and anti-MCV antibodies with response to treatment and radiographic progression in an RA population treated with either methotrexate or baricitinib: post-hoc analyses from RA-BEGIN
por: López-Romero, Pedro, et al.
Publicado: (2020)

Membrane Transporters as Mediators of Cisplatin Effects and Side Effects
por: Ciarimboli, Giuliano
Publicado: (2012)

Fishing for protective compounds
por: Ciarimboli, Giuliano
Publicado: (2020)

Regulation Mechanisms of Expression and Function of Organic Cation Transporter 1
por: Ciarimboli, Giuliano
Publicado: (2021)

Anticancer Platinum Drugs Update
por: Ciarimboli, Giuliano
Publicado: (2021)

Physiology, Biochemistry, and Pharmacology of Transporters for Organic Cations
por: Ciarimboli, Giuliano
Publicado: (2021)

Physiology, Biochemistry and Pharmacology of Transporters for Organic Cations 2.0
por: Ciarimboli, Giuliano
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5a6ui42qvo532ok16605q5bnga